Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. - Wikidata - awgldk - TriplyDB

Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

http://www.wikidata.org/entity/Q37058731

about

Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field Unveiling changes in the landscape of patient populations in cancer early drug development A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report The role of preclinical animal models in breast cancer drug development.Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies Phase 0 clinical trials in oncology new drug development.Phase 0 Workshop at the 20th EORTC-NCI-AACR Symposium, Geneva.Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.How can grafted breast cancer models be optimized?Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents.Designing phase 0 cancer clinical trials.Liquid Chromatographic Determination of NSC 737664 (ABT-888: an Inhibitor of Poly(ADP-ribose) Polymerase (PARP)) in Plasma and Urine in a Phase 0 Clinical Trial Evaluation of surrogate tissues as indicators of drug activity in a melanoma skin model Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.Phase 0 clinical studies in oncology.The statistics of phase 0 trials.Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development.Dose-toxicity models in oncology.Re-overcoming barriers in translating biomarkers to clinical practice.Radiolabeling strategies for tumor-targeting proteinaceous drugs.Therapies for triple negative breast cancer.The application of human phase 0 microdosing trials: A systematic review and perspectives.Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions.Analysis of FDA-approved imaging agents.Role of Phase 0 trials in drug development.Ethical responsibility of phase 0 trials.

P2860

Q26822431-AFFB5380-824A-4221-907A-4985A1107E4B Q28073826-245857F6-80A9-453F-B019-64160F114E9F Q33415790-A3957B64-0CBA-4A4C-ACAF-9E31198834E3 Q33555575-1388456B-0029-416F-8165-7FBECB30C28C Q33985780-E29513DE-1ABC-4845-A9D5-9B0128DD71CA Q34941964-CD2EA4BC-A638-4AAC-8C6A-439171779942 Q35602195-AC417707-565B-4797-984D-6A18321EC5C9 Q35641721-8B07760D-74CC-4689-83BE-BB07088BED8F Q35760911-C360FCEC-392C-47F5-ABA4-E4F7C1FD0DF3 Q36021866-17041E86-E3CA-44CE-A8A4-C6F0E86D6443 Q36732115-6F657E55-319E-4987-8547-84DAD8D1A46D Q37041307-7B9C4DE0-9D67-4DD9-B5E1-47945668FEF8 Q37148914-563E4E87-62CF-4512-B273-2A877E68B543 Q37337123-4793DD50-E7B0-49D3-BD79-DE6C829AF55D Q37358487-DCB3DC71-AB48-45A3-A1D4-5A08BA821D3B Q37515513-CECDAE32-7604-48F7-A865-3CC733B3F1BF Q37552670-5F5691D8-E658-4792-9296-0AFF5B57C4A6 Q37701128-09AC9CB6-A803-4F30-8C2B-AE249AD6C82E Q37829437-17E1886B-B4E6-433C-8A09-B6B77866F346 Q38088713-82FCBB69-AECE-4487-A565-ACEC2337A594 Q38189541-71FDABF4-4224-456C-B855-001DF470E5F5 Q38424397-4E6ACF23-B322-438E-A294-3330D081B2C9 Q38597205-E87401CE-B0EE-4E4E-AEC8-C00CB846938F Q38633504-A7227121-EB2D-4241-925C-06D4E1A759B3 Q38739939-DF88DFEE-1609-4D01-8710-81F14CB42214 Q39934032-AE8F13CB-26D6-4200-A14E-2668DBB0E40F Q42407837-6819928E-3ED3-4D4A-822D-E57D0C513B3F

P2860

Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

http://www.wikidata.org/entity/Q37058731

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase 0 clinical trials in can ...... guidance to clinical practice.

@en

Phase 0 clinical trials in can ...... guidance to clinical practice.

@nl

type

label

Phase 0 clinical trials in can ...... guidance to clinical practice.

@en

Phase 0 clinical trials in can ...... guidance to clinical practice.

@nl

prefLabel

Phase 0 clinical trials in can ...... guidance to clinical practice.

@en

Phase 0 clinical trials in can ...... guidance to clinical practice.

@nl

P1433

Q37058731-74859EC3-8D19-44EC-9392-CD31BBA37CB1

P1476

Q37058731-CD508409-E450-40BB-A046-EB564C2BC9C9

P2093

Q37058731-021A4187-C62A-437E-B164-BA2A234DEFC0

Q37058731-1670DE29-C7B7-4E8C-BB2A-34831BE6861D

Q37058731-27689AE5-396F-46CF-9CDA-2A61F7650FDF

Q37058731-33D5AD34-4C25-47A2-888D-917BBC815532

Q37058731-40433E35-1AEE-450D-AD2A-CEABA30D6C2B

Q37058731-45FD704A-49EF-4B3A-80B3-37495210B715

Q37058731-537FCD64-EA22-45CD-A6B0-FAC93644E4F1

Q37058731-55736FC5-C1DE-49F7-BDA7-B9C84E32DAA0

Q37058731-608D86A3-8062-469B-8C73-C348BAD8104D

Q37058731-691C0D9A-0E8B-472A-A318-B82FB7BF6759

P304

Q37058731-6A8EE1FA-2BF2-4EB4-97A6-F424880FB3CE

P31

Q37058731-4975E867-1E02-4CBD-B88A-3B4E5413BC6D

P356

Q37058731-8823C113-BCDD-4083-9A82-C0267B9F8D21

P433

Q37058731-16326E0E-6BCA-460B-8C92-65660ADB71C5

P478

Q37058731-3DF8A0F9-8A70-4D9D-B75E-6ED324CA7525

P577

Q37058731-97492BF3-1169-4BCB-91D2-08B2A6A17D83

P698

Q37058731-BCEDB0FE-29A8-4E89-8BA8-3C4858271CF1

P356

P1433

Molecular Interventions: pharmacological perspectives from biology, chemistry and genomics

P1476

Phase 0 clinical trials in can ...... guidance to clinical practice.

@en

P2093

Alice Chen

http://www.w3.org/2001/XMLSchema#string

Anthony J Murgo

http://www.w3.org/2001/XMLSchema#string

James H Doroshow

http://www.w3.org/2001/XMLSchema#string

Jay Ji

http://www.w3.org/2001/XMLSchema#string

Jerry Collins

http://www.w3.org/2001/XMLSchema#string

Joseph E Tomaszewski

http://www.w3.org/2001/XMLSchema#string

Larry Rubinstein

http://www.w3.org/2001/XMLSchema#string

Lee Helman

http://www.w3.org/2001/XMLSchema#string

Martin Gutierrez

http://www.w3.org/2001/XMLSchema#string

Mel Simpson

http://www.w3.org/2001/XMLSchema#string

P304

325-334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/MI.7.6.9

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18199854

http://www.w3.org/2001/XMLSchema#string